Parallel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Parallel Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$524	Sell	20 -27	-57%	-$629	﹤0.01%	3785
2026 Q1	$1.11K	Buy	47 +45	+2,250%	+$1.15K	﹤0.01%	3522
2025 Q4	$58	Buy	+2	New	+$51	﹤0.01%	3567
2025 Q2	–	Sell	-14	Closed	-$219	–	3551
2025 Q1	$219	Sell	14 -14	-50%	-$197	﹤0.01%	3368
2024 Q4	$390	Buy	+28	New	+$307	﹤0.01%	3269
2023 Q3	–	Sell	-32	Closed	-$305	–	3369
2023 Q2	$305	Buy	+32	New	+$355	﹤0.01%	3192
2022 Q3	–	Sell	-7	Closed	–	–	3127
2022 Q2	$0	Buy	+7	New	+$144	﹤0.01%	2978

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Parallel Advisors's ARQT Position: Q2 2026 in Review

Parallel Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 57% in Q2 2026, selling an estimated $629 and leaving 20 shares worth $524. The position accounts for ﹤0.01% of the portfolio, ranked #3785.

Parallel Advisors first reported a position in ARQT in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.11K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Parallel Advisors held 20 shares of Arcutis Biotherapeutics worth $524 as of Q2 2026.
Parallel Advisors sold 27 Arcutis Biotherapeutics shares in Q2 2026, an estimated $629.
Arcutis Biotherapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3785 holding.
Parallel Advisors first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 7 quarters since.
Parallel Advisors's Arcutis Biotherapeutics position peaked at $1.11K in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.